Melanotan II: Side Effects & Safety

Melanotan II is not approved for medical use in any country. It is a synthetic non-selective melanocortin-receptor agonist (MC1R, MC3R, MC4R, MC5R) originally developed as a research tool. Health authorities including the FDA, EMA, UK MHRA, and Australian TGA have issued public warnings against its use. The published case-report literature documents serious adverse events that distinguish Melanotan II from most other peptides covered on this site — this is one of the few research peptides where the safety case alone justifies avoiding it.

Melanotan II is not on the agenda for the July 23–24, 2026 FDA Pharmacy Compounding Advisory Committee 503A bulks list meeting. It has no pathway to legitimate compounded availability in the US. The Melanotan II sold online is from unregulated suppliers with no quality control — contamination and dose inaccuracy are real and documented risks.

For an FDA-approved selective MC4R agonist with a much better-characterized safety profile, see PT-141 (bremelanotide). For the eumelanin-only selective MC1R agonist with FDA orphan-drug approval, see Melanotan I (afamelanotide / Scenesse).

The following events have been reported in peer-reviewed case reports and case series involving Melanotan II:

• Melanoma cases: multiple case reports describe melanoma diagnosis in individuals using Melanotan II, including cases with rapid nevus change after starting the peptide.^[1] The causal relationship is not established, but the case literature has prompted dermatology societies to advise against use.
• Eruptive nevi and dysplastic nevi: reports of rapid emergence of new pigmented lesions after Melanotan II use.^[2]
• Priapism (males): prolonged painful erection requiring emergency intervention has been reported after Melanotan II use.^[3]
• Renal infarction: at least one published case linked to Melanotan II.^[4]
• Rhabdomyolysis: rare cases reported.
• Posterior reversible encephalopathy syndrome (PRES): isolated case reports.
• Hyperpigmentation that does not fully reverse after discontinuation, especially in pre-existing nevi.

These events are not common, but the existence of multiple peer-reviewed case reports of severe outcomes — combined with the unregulated supply chain — is the basis for international regulatory warnings.

• U.S. FDA: Melanotan II is not approved as a drug or as a cosmetic. Marketing or selling it for human use is illegal under the Food, Drug, and Cosmetic Act.
• UK MHRA: issued multiple public warnings citing nausea, melanoma concerns, and quality-control problems with the unregulated supply.
• Australian TGA: classified Melanotan II as a Schedule 4 prescription-only substance; importation for personal use is restricted.
• EU EMA / national authorities: repeated warnings against use; not authorized in any EU member state.
• Norwegian Medicines Agency and others: have linked Melanotan II to acute health emergencies in users.

• Personal or family history of melanoma, atypical mole syndrome, or dysplastic nevi: absolute contraindication.
• Multiple existing nevi (> ~50): relative contraindication — risk of missing melanoma changes.
• Pregnancy and breastfeeding: contraindicated.
• Cardiovascular disease, uncontrolled hypertension, history of arrhythmia, ischemic events: contraindicated.
• Liver or kidney disease.
• Active psychiatric disorders requiring acute pharmacotherapy.
• Children and adolescents.

Drug interactions

• Other melanocortin agonists (PT-141, Melanotan I): do not combine.
• PDE5 inhibitors (sildenafil, tadalafil): additive effect on erection; priapism risk in males.
• Antihypertensives: unpredictable BP interactions.
• Stimulants: theoretical additive effects on heart rate and BP.

• Any new or changing mole during or after Melanotan II use: immediate dermatology evaluation. Do not assume it is "just" pigmentation from the peptide.
• Persistent erection > 4 hours (priapism): emergency department immediately — this is a urological emergency.
• Severe nausea, abdominal pain, decreased urination: evaluate for renal injury.
• Severe muscle pain, dark urine: evaluate for rhabdomyolysis (CK, renal function).
• Severe headache, vision changes, confusion: emergency evaluation — rule out PRES or hypertensive emergency.
• Allergic reaction: emergency care.
• Generalized: discontinue. The peer-reviewed case-report literature is strong enough that discontinuation is the safest response to any concerning new symptom.

See the Melanotan II overview, Melanotan I (FDA-approved Scenesse) as a safer-profile alternative for narrow indications, and PT-141 for the FDA-approved selective MC4R agonist.